Feasibility of Using Recombinant Factor VIIa in Continuous Infusion

Summary

Recombinant factor Vila (rFVIIa; NovoSeven^®) is a recent addition to the hemostatic alternatives for the treatment of hemophiliacs with inhibitors. A drawback in the use of rFVIIa has been its half-life of only about 2 h, which necessitates very frequent and punctual injections. We evaluated the stability of reconstituted, but not further diluted, rFVIIa in 3 infusion systems (WalkMed^TM 350 and CADD^®-Plus minipumps and Meddex 2001 syringe pump). The factor VII (F VII) activity was maintained for at least 3 days at room temperature with only a minor and clinically insignificant increase in oxidized forms of rFVIIa and minimal leaching of the plastic softeners di-butylphthalate and di-octylphthalate after 24–48 h. Addition of heparin, 5–10 U/ml, to reconstituted rFVIIa caused a loss of about 50% of the activity within 4 h of storage in the infusion system, whereas low molecular weight heparin had no such effect. Repeated samples showed that the infusion systems maintained sterility. Reconstituted rFVIIa did not support bacterial growth when inoculated with Staphylococcus aureus or Escherichia coli to any greater extent than did reconstituted factor VIII, lidocaine in saline or heparin in saline. Two patients were treated with continuous infusion of rFVIIa on 4 occasions (total knee arthroplasty, wound revision, and twice straightening of a 90° contracture of the knee under general anaesthesia). A preoperative pharmacokinetic evaluation was performed, and the clearance was used to calculate the maintenance dose, aiming at a FVII level of 10 U/ml, which proved to be a hemostatic level. The first patient had no change in the clearance during the two treatment episodes. He suffered from repeated thrombophlebitis at the infusion site. The second patient had a progressive decrease of the clearance from 86.4 to 24.7 ml/h/kg. He received during the first treatment a parallel infusion with heparin (≈250 U/24 h) to the same venous access and did not develop thrombophlebitis during 3.5 days of therapy. For the second episode low molecular weight heparin was added directly to the infusion bag, and no adverse effects were observed. Continuous infusion with rFVIIa is thus feasible with the minipumps used by us, eliminates the need for 2 h injections and reduces the total dose of rFVIIa by 50–75%, depending on the behaviour of the clearance.

• References

• 1 Martinowitz U, Schulman S. Continuous infusion of coagulation products. Int J Pediatr Hematol Oncol 1994; 1: 471-478
• 2 Martinowitz U, Schulman S, Gitel S, Horoszowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 1992; 82: 729-734
• 3 Schulman S, Varon D, Keller N, Gitel S, Martinowitz U. Monoclonal purified F VIII for continuous infusion: Stability, microbiological safety and clinical experience. Thromb Haemost 1994; 72: 403-407
• 4 Schulman S, Keller N, Gitel N, Ravid B, Varon D, Martinowitz U. The suitability of recombinant F VIII (Kogenate^®) for continuous infusion -stability and bacteriological safety. Br J Haematol 1994; 87 (Suppl. 01) 185 (abstract)
• 5 Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickies FR. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease. Thromb Haemost 1994; 71: 173-179
• 6 Schulman S, Gitel S, Zivelin A, Mandalaki T, Katsarou O, Varon D, Martinowitz U. The feasibility of using concentrates containing factor IX for continuous infusion. Haemophilia 1995; 1: 103-110
• 7 Gordon EM, Al-Batniji F, Goldsmith JC. Continuous infusion of monoclonal antibody-purified factor VIII: Rational approach to serious hemorrhage in patients with allo-/autoantibodies to factor VIII. Am J Hematol 1994; 45: 142-145
• 8 Hedner U, Glazer S, Pingel K, Alberts KA, Blomback M, Schulman S, Johnsson H. Successful use of recombinant factor Vila in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193
• 9 Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmacodynamics of recombinant factor Vila. Clin Pharmacol Ther 1994; 55: 638-648
• 10 Broze G, Majerus PT. Human factor VII. Methods Enzymol 1981; 10: 228-237
• 11 Gringeri A, Santagostino E, Mannucci PM. Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody. Haemostasis 1991; 21: 1-4
• 12 Hedner U. Experiences with recombinant factor Vila in haemophiliacs. In: Biotechnology of plasma proteins Albertini A, Lenfant CL, Mannucci PM, Sixma JJ. eds. Curr Stud Hematol Blood Transf; Karger, Basel: 1991. 58 63-68
• 13 Ingerslev J, Sneppen O, Knudsen L, Sindet-Pedersen S. Effect of recombinant factor Vila (rFVIIa) in surgical procedures in haemophilia A patients with inhibitors and congenital factor VII deficiency. In: 24. Hamophilie-Symposium, Hämburg 1994. Scharrer/Schramm eds. Springer; Berlin -Heidelberg: 1994: 122-125